Blood hematologic parameters of cynomolgus monkeys unilaterally irradiated at 5 Gy with 60Co gamma radiation
Parameters . | 4F-treated group, mean ± SD (range) . | Control group, mean ± SD (range) . |
|---|---|---|
| Duration of leukopenia, WBC count less than 1 × 109/L, d | 1.5 ± 2.6 (0-6)* | 7.5 ± 2.9 (5-12) |
| Duration of neutropenia, ANC count less than 0.5 × 109/L, d | 1.75 ± 3 (0-7)* | 9 ± 2.5 (5-12) |
| Duration of lymphopenia, LY count less than 1 × 109/L, d | 16 ± 8 (18-36)* | 47 ± 16 (27-66) |
| Duration of thrombocytopenia, PLT count less than 20 × 109/L, d | 0 | 13.2 ± 10.5 (5-31) |
| Duration de thrombocytopenia, PLT count less than 50 × 109/L, d | 0 | 23.5 ± 20 (9-58) |
| Duration of anemia, hemoglobin level less than 10 g/dL, d | 6.2 ± 6 (0-13) | 45.2 ± 13.6 (33-66) |
| Time to baseline neutrophil recovery, d | 26* | 68 ± 30 (34-105) |
| Time to baseline platelet recovery, d | NA | 85 ± 20 (63-110) |
| Blood transfusion dependence, in blood units | 0 | 1.75 ± 0.8 (1-3) |
Parameters . | 4F-treated group, mean ± SD (range) . | Control group, mean ± SD (range) . |
|---|---|---|
| Duration of leukopenia, WBC count less than 1 × 109/L, d | 1.5 ± 2.6 (0-6)* | 7.5 ± 2.9 (5-12) |
| Duration of neutropenia, ANC count less than 0.5 × 109/L, d | 1.75 ± 3 (0-7)* | 9 ± 2.5 (5-12) |
| Duration of lymphopenia, LY count less than 1 × 109/L, d | 16 ± 8 (18-36)* | 47 ± 16 (27-66) |
| Duration of thrombocytopenia, PLT count less than 20 × 109/L, d | 0 | 13.2 ± 10.5 (5-31) |
| Duration de thrombocytopenia, PLT count less than 50 × 109/L, d | 0 | 23.5 ± 20 (9-58) |
| Duration of anemia, hemoglobin level less than 10 g/dL, d | 6.2 ± 6 (0-13) | 45.2 ± 13.6 (33-66) |
| Time to baseline neutrophil recovery, d | 26* | 68 ± 30 (34-105) |
| Time to baseline platelet recovery, d | NA | 85 ± 20 (63-110) |
| Blood transfusion dependence, in blood units | 0 | 1.75 ± 0.8 (1-3) |
Populations for the two groups; n = 4 for the 4F-treated group; n = 4 for the control group. Statistical significance (P < .05) was reached for all parameters between treated and control groups. 4F indicates recombinant human SCF + MGDF + FL + IL-3 (50 μg/kg each) given intravenously 2 hours after TBI; and NA, not applicable.
Three treated animals did not display any leukopenia.